Acknowledgement
Supported by : 과기부
References
- Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61;759-767, 1990 https://doi.org/10.1016/0092-8674(90)90186-I
- Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, Lucibello FC, Murday VA, Rider SH, Scambler P, et al:Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328;614-616, 1987 https://doi.org/10.1038/328614a0
- Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF: Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 340;626-630, 1992 https://doi.org/10.1016/0140-6736(92)92169-G
- Kerr D: Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 3;615-622, 2003. https://doi.org/10.1038/nrc1147
- Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276;1268-1272, 1997 https://doi.org/10.1126/science.276.5316.1268
- Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185;2043-2051, 1997 https://doi.org/10.1084/jem.185.12.2043
- Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack RW, Jung G, Kosmatopoulos K, Mateo L, Suhrbier A, Lemonnier FA, Langlade-Demoyen P: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29;3112-3121, 1999 https://doi.org/10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q
- Lewin AR, Reid LE, McMahon M, Stark GR, Kerr IM: Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 199;417-423, 1991 https://doi.org/10.1111/j.1432-1033.1991.tb16139.x
- Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81;1009-1016, 1999 https://doi.org/10.1038/sj.bjc.6690800
- Mahvi DM, Madsen JA, Witt PL, Sondel PM: Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer. Cancer Immunol Immunother 40;311-314, 1995 https://doi.org/10.1007/BF01519631
- Dansky-Ullmann C, Salgaller M, Adams S, Schlom J, Greiner JW:Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta. Cytokine 7;118-129, 1995 https://doi.org/10.1006/cyto.1995.1016
- Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J: Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression. Immunol Lett 36;179-185, 1993 https://doi.org/10.1016/0165-2478(93)90050-C
- Firat H, Tourdot S, Ureta-Vidal A, Scardino A, Suhrbier A, Buseyne F, Riviere Y, Danos O, Michel ML, Kosmatopoulos K, Lemonnier FA: Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol 10;3064-3074, 2001
- Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L: Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J.Clin. Invest 110;453-462, 2002. https://doi.org/10.1172/JCI200214071
- Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K: Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGEA1,-A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol 169;575-580, 2002 https://doi.org/10.4049/jimmunol.169.1.575
- Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol 168;5900-5906, 2002 https://doi.org/10.4049/jimmunol.168.11.5900
- Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C: ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99;2100-2106, 2002 https://doi.org/10.1182/blood.V99.6.2100
- Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K: Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur. J. Immunol 11;3261-3270, 2001.
- Brinster C, Muguet S, Lone YC, Boucreux D, Renard N, Fournillier A, Lemonnier F, Inchauspe G: Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA- expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34;1206-1217, 2001 https://doi.org/10.1053/jhep.2001.29304
- Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl- XL. Immunity 3;87-98, 1995. https://doi.org/10.1016/1074-7613(95)90161-2
- Harding FA, Allison JP: CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177;1791-1796, 1993. https://doi.org/10.1084/jem.177.6.1791
- Malek TR, Yu A, Scibelli P, Lichtenheld MG, Codias EK: Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J Immunol 166;1675-1683, 2001 https://doi.org/10.4049/jimmunol.166.3.1675
- Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTLmediated protective tumor immunity. J Exp Med 183;283-287, 1996. https://doi.org/10.1084/jem.183.1.283
- Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183;317-322, 1996 https://doi.org/10.1084/jem.183.1.317
- Young JW, Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183;7-11, 1996 https://doi.org/10.1084/jem.183.1.7
- Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4;328-332, 1998. https://doi.org/10.1038/nm0398-328
- Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G:Vaccination with mage-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190;1669-1678, 1999 https://doi.org/10.1084/jem.190.11.1669
- Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P: Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165;2651-2656, 2000 https://doi.org/10.4049/jimmunol.165.5.2651
- Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ: Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60;6995-7001, 2000
- Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O, Caput D, Huez GA, Wathelet MG: Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem 270;23860-23866, 1995 https://doi.org/10.1074/jbc.270.40.23860
- Hisamatsu T, Watanabe M, Ogata H, Ezaki T, Hozawa S, Ishii H, Kanai T, Hibi T: Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res 59;5927-5931, 1999
- Clave E, Carosella ED, Gluckman E, Socie G: Radiation- enhanced expression of interferon-inducible genes in the KG1a primitive hematopoietic cell line. Leukemia 11;114-119, 1997 https://doi.org/10.1038/sj.leu.2400528
- Daido H, Zhou MY, Gomez-Sanchez CE: Angiotensin stimulates the expression of interferon-inducible genes in H295R cells. Mol Cell Endocrinol 176;21-27, 2001 https://doi.org/10.1016/S0303-7207(01)00478-6